Poly Medicure Limited (POLYMED)
ENCLOSED
Press Release - Q1FY27
- Consolidated revenue grew 30.3% y-y to Rs 525.4 Cr; standalone revenue up 12.3% y-y to Rs 431.1 Cr
- Consolidated operating EBITDA margin at 24.1% within guidance; standalone margin at 28.0% above guidance
- Domestic revenue grew 16.2% y-y; international revenue up 36.7% y-y
- Average price increase of 4-5% in Q1 FY27 vs Q4 FY26
- Six new products launched in Q1 FY27 across infusion therapy and critical care
- Strong cash position of Rs 854.7 Cr as of June 30, 2026
- ESG progress: 18% reduction in scope 2 emissions, 6x growth in solar power generation
- Key business updates: CEO appointments, 13K+ stent deployments, 840+ patients enrolled in clinical registry
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 POLYMED — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add POLYMED to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Poly Medicure Limited
Important.
The summary above is generated automatically from Poly Medicure Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.